The use of extrapolation based on modeling and simulation to support high-dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft-tissue infections.


Journal

CPT: pharmacometrics & systems pharmacology
ISSN: 2163-8306
Titre abrégé: CPT Pharmacometrics Syst Pharmacol
Pays: United States
ID NLM: 101580011

Informations de publication

Date de publication:
06 2021
Historique:
revised: 29 01 2021
received: 02 12 2021
accepted: 31 01 2021
pubmed: 10 3 2021
medline: 22 1 2022
entrez: 9 3 2021
Statut: ppublish

Résumé

A model-informed drug development approach was used to select ceftaroline fosamil high-dose regimens for pediatric patients with complicated skin and soft-tissue infections caused by Staphylococcus aureus with a ceftaroline minimum inhibitory concentration (MIC) of 2 or 4 mg/L. Steady-state ceftaroline concentrations were simulated using a population pharmacokinetics (PK) model for ceftaroline fosamil and ceftaroline including data from 304 pediatric subjects and 944 adults. Probability of target attainment (PTA) for various simulated pediatric high-dose regimens and renal function categories were calculated based on patients achieving 35% fT>MIC (S. aureus PK/pharmacodynamic target for 2-log

Identifiants

pubmed: 33687148
doi: 10.1002/psp4.12608
pmc: PMC8213416
doi:

Substances chimiques

Anti-Bacterial Agents 0
Cephalosporins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

551-563

Informations de copyright

© 2021 Pfizer R&D UK Limited. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

Références

CPT Pharmacometrics Syst Pharmacol. 2016 Mar;5(3):93-122
pubmed: 27069774
Pediatr Infect Dis J. 2016 Aug;35(8):e239-47
pubmed: 27164462
Braz J Infect Dis. 2014 Mar-Apr;18(2):187-95
pubmed: 24513484
Drugs. 2016 Nov;76(17):1659-1674
pubmed: 27766567
Antimicrob Agents Chemother. 2017 Aug 24;61(9):
pubmed: 28630196
J Clin Pharmacol. 2017 Mar;57(3):345-355
pubmed: 27510635
J Antimicrob Chemother. 2016 Dec;71(12):3575-3584
pubmed: 27585969
Nephron. 1976;16(1):31-41
pubmed: 1244564
Lancet Infect Dis. 2015 Feb;15(2):161-71
pubmed: 25539586
Diagn Microbiol Infect Dis. 2016 Oct;86(2):194-9
pubmed: 27461798
J Am Soc Nephrol. 2009 Mar;20(3):629-37
pubmed: 19158356
Antimicrob Agents Chemother. 2015 Dec;59(12):7873-7
pubmed: 26416860
Br J Clin Pharmacol. 2019 Apr;85(4):659-668
pubmed: 30707770
Clin Pharmacol Drug Dev. 2019 Jul;8(5):682-694
pubmed: 31044546
J Clin Pharmacol. 2019 Sep;59 Suppl 1:S104-S111
pubmed: 31502691
J Clin Pharmacol. 2016 Nov;56(11):1326-1334
pubmed: 27040726
Pediatr Nephrol. 2009 Jan;24(1):67-76
pubmed: 18846389
J Antimicrob Chemother. 2019 Apr 1;74(4):1086-1091
pubmed: 30597021
J Antimicrob Chemother. 2019 Feb 1;74(2):425-431
pubmed: 30380060
J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii11-8
pubmed: 21482565
Clin Pharmacol Ther. 2019 Apr;105(4):899-911
pubmed: 30653670
Pediatrics. 2011 Nov;128(5):e1242-9
pubmed: 22025597
Int J Antimicrob Agents. 2010 Jul;36(1):28-32
pubmed: 20444576
Int J Antimicrob Agents. 2015 Dec;46(6):682-8
pubmed: 26545441
Pediatr Infect Dis J. 2016 Jul;35(7):760-6
pubmed: 27078119
Clin Pharmacokinet. 2015 Sep;54(9):915-31
pubmed: 25940827
Int J Clin Pharmacol Ther. 2015 Aug;53(8):681-91
pubmed: 26152131
Drugs. 2018 Feb;78(2):231-244
pubmed: 29218501
J Chemother. 2014 Aug;26(4):202-10
pubmed: 24070006
Front Pediatr. 2018 Oct 29;6:325
pubmed: 30420947
Expert Opin Drug Metab Toxicol. 2014 Dec;10(12):1741-50
pubmed: 25347329
Clin Microbiol Infect. 2019 Nov;25(11):1429.e1-1429.e4
pubmed: 30980925
Antimicrob Agents Chemother. 2006 Apr;50(4):1376-83
pubmed: 16569855
Antimicrob Agents Chemother. 2015 Oct 26;60(1):343-7
pubmed: 26503659
J Clin Pharmacol. 2014 Jul;54(7):742-52
pubmed: 24431097

Auteurs

Phylinda L S Chan (PLS)

Pfizer, Sandwich, Kent, UK.

Lynn McFadyen (L)

Pfizer, Sandwich, Kent, UK.

Andrea Quaye (A)

Pfizer, Tadworth, Surrey, UK.

Heidi Leister-Tebbe (H)

Pfizer, Collegeville, Pennsylvania, USA.

Victoria M Hendrick (VM)

Pfizer, Sandwich, Kent, UK.

Jennifer Hammond (J)

Pfizer, Collegeville, Pennsylvania, USA.

Susan Raber (S)

Pfizer, La Jolla, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH